What dose counts as a microdose of tirzepatide?

You've seen the phrase everywhere, but the starting pen is already 2.5mg

Picture this: you've come across 'microdosing Mounjaro' on a forum or social media, and you're wondering whether a very small dose might ease you in more gently, cost less, or avoid side effects. It's a reasonable thing to wonder. The honest answer is that the conversation online is running ahead of the evidence.

Mounjaro is supplied in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. The 2.5mg pen is already the gentlest rung on that ladder, its job is to let your body adjust to tirzepatide before the dose is increased, not to produce significant weight loss on its own. When people online use the word 'microdose', they generally mean something below that 2.5mg mark, achieved by partially depressing a pen or diluting the medicine, and if you want to understand what dose is actually considered a microdose of tirzepatide, the picture is more specific than most forum posts suggest. Neither approach is described or validated in the Mounjaro Summary of Product Characteristics on the eMC.

The pre-filled KwikPen is designed to deliver a single, metered weekly dose. It is not calibrated for partial injections. Attempting to draw a fraction of the dose introduces measurement error and risks contamination, two problems a regulated pharmacy and prescriber exist to prevent. Keep the pen in the fridge door, in the box, until injection day: that routine matters for a reason.

Where the 'microdosing' idea came from, and why it doesn't translate to licensed use

The word 'microdosing' entered mainstream awareness through discussions about psychedelic compounds, where very small, sub-perceptual doses were taken for mood or focus. Some people began applying the same logic to GLP-1 and dual-agonist medicines, suggesting that tiny amounts might suppress appetite with fewer side effects.

There is no published clinical trial data supporting sub-2.5mg tirzepatide doses for weight management. The SURMOUNT-1 trial, which involved thousands of adults and informed NICE's recommendation of tirzepatide (TA1026), tested doses from 5mg upward to 15mg after an initial four-week period at 2.5mg. The 2.5mg starter period produced modest effects; doses below it were not studied. Extrapolating from a trial design to an unlicensed practice is not the same as evidence.

There's also a sourcing problem. Sub-licensed doses require either manipulating a pre-filled pen or obtaining a compounded preparation. Compounded tirzepatide is not authorised in the UK, if you encounter it for sale, that is a red flag. You can explore what microdosing Mounjaro actually involves in more depth, but the clinical picture doesn't change: UK prescribers work within the licensed schedule.

What the licensed 2.5mg starting dose is actually for

The first four weeks on Mounjaro serve a specific purpose: they give your gut and appetite-regulation system time to adapt to a dual GIP and GLP-1 receptor agonist for the first time. Nausea, the most commonly reported early side effect, tends to be most noticeable in the first weeks after starting or after a dose increase. The 2.5mg period is designed to reduce that burden, not to produce the weight-loss results you'll read about in trial data.

Those results (an average body-weight reduction of around 20–21% at 15mg over 72 weeks in the SURMOUNT-1 trial) reflect the full titration journey, not the starting point. A prescriber considers your whole health picture when deciding how quickly to titrate and at which dose to maintain you. That's different from a fixed 'microdose' taken indefinitely. If cost is part of what's drawing you toward lower doses, it's worth reading about how Mounjaro is priced across the dose range, the conversation is more nuanced than it first appears.

Side effects at any dose should be discussed with your prescriber rather than managed by independently reducing your dose. The NICE appraisal of tirzepatide (TA1026) sets out the clinical framework within which prescribers work, and that framework does not include sub-licensed doses.

What a legitimate lower-dose approach actually looks like

If your concern is tolerability (a worry our prescribers hear regularly from people who've had a rough experience on another GLP-1 medicine) the licensed answer is to start at 2.5mg and titrate slowly. Prescribers can keep you at 2.5mg for longer than the standard four weeks if your side-effect picture warrants it. That is a clinically supported, licensed, evidence-based approach to a gentler start, and our guidance on micro dose tirzepatide explains how that differs from the unlicensed practices circulating online. It does not require manipulating a pen or sourcing anything outside the regulated supply chain.

People who are already on Mounjaro and want to understand the full tirzepatide dosing schedule will find that each step up is reviewed clinically, not automatic. A prescriber looks at your response, any side effects you've reported, and your overall progress before recommending an increase. That review is what a clinically supervised Mounjaro journey looks like from the inside. If you're curious whether the licensed route might suit you, speaking to our prescribers is the logical next step, no waiting list, same-day clinical review.